XTANT MEDICAL HOLDINGS, INC. Xtant Medical Holdings, Inc. Share Price
Equities
XTNT
US98420P3082
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8946 USD | -3.81% |
|
-1.58% | -20.83% |
| 30/04 | Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds | CI |
| 01/04 | Xtant Medical Files $150 Million Mixed Shelf; Shares Fall | MT |
| Sales 2024 * | 115M 9.59B | Sales 2025 * | 130M 10.87B | Capitalization | 116M 9.72B |
|---|---|---|---|---|---|
| Net income 2024 * | -8M -667M | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.01 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.89 x |
| P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
-179
x | Employees | 211 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xtant Medical Holdings, Inc.
More press releases
| 1 day | -3.81% | ||
| 1 week | -1.58% | ||
| 1 month | -23.54% | ||
| 3 months | -2.76% | ||
| 6 months | -23.54% | ||
| Current year | -20.83% |
1 week
0.87
0.97
1 month
0.761.14
Current year
0.761.31
1 year
0.601.45
3 years
0.432.38
5 years
0.436.58
10 years
0.4397.20
| Managers | Title | Age | Since |
|---|---|---|---|
Sean Browne
CEO | Chief Executive Officer | 58 | 07/19/07 |
Scott Neils
DFI | Director of Finance/CFO | 40 | 01/19/01 |
| Chief Operating Officer | - | 16/23/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 16/23/16 | |
John Bakewell
BRD | Director/Board Member | 62 | 01/18/01 |
Robert McNamara
BRD | Director/Board Member | 67 | 01/18/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 0.8946 | -3.81% | 36,184 |
| 29/24/29 | 0.93 | -2.11% | 53,497 |
| 26/24/26 | 0.95 | +5.38% | 61,122 |
| 25/24/25 | 0.9015 | +1.29% | 18,428 |
| 24/24/24 | 0.89 | -2.09% | 35,061 |
Delayed Quote Nyse, April 01, 2024 at 01:30 am IST
More quotes
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8946
USD
Average target price
1.925
USD
Spread / Average Target
+115.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.83% | 116M | |
| +12.37% | 128B | |
| -9.23% | 10.69B | |
| +2.17% | 8.93B | |
| +18.79% | 7.32B | |
| +20.77% | 4.82B | |
| +6.97% | 3.4B | |
| -1.41% | 3.03B | |
| -5.07% | 2.23B | |
| -4.22% | 2.13B |
- Stock Market
- Equities
- XTNT Stock
